Stanniocalcin-1 Hormone in Nonpreeclamptic and Preeclamptic Pregnancy : Clinical, Life-Style, and Genetic Modulators

Show full item record



Permalink

http://hdl.handle.net/10138/174088

Citation

Juhanson , P , Rull , K , Kikas , T , Laivuori , H , Vaas , P , Kajantie , E , Heinonen , S & Laan , M 2016 , ' Stanniocalcin-1 Hormone in Nonpreeclamptic and Preeclamptic Pregnancy : Clinical, Life-Style, and Genetic Modulators ' Journal of Clinical Endocrinology and Metabolism , vol. 101 , no. 12 , pp. 4799-4807 . DOI: 10.1210/jc.2016-1873

Title: Stanniocalcin-1 Hormone in Nonpreeclamptic and Preeclamptic Pregnancy : Clinical, Life-Style, and Genetic Modulators
Author: Juhanson, Peeter; Rull, Kristiina; Kikas, Triin; Laivuori, Hannele; Vaas, Pille; Kajantie, Eero; Heinonen, Seppo; Laan, Maris
Contributor: University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Children's Hospital
University of Helsinki, Department of Obstetrics and Gynegology
Date: 2016-12
Language: eng
Number of pages: 9
Belongs to series: Journal of Clinical Endocrinology and Metabolism
ISSN: 0021-972X
URI: http://hdl.handle.net/10138/174088
Abstract: Context and Objectives: The study represents the first comprehensive analysis of Stanniocalcin-1 (STC1) hormone in human pregnancy, assessing clinical, lifestyle, and genetic determinants of circulating STC1 at term. Design, Setting, and Participants: Participants included women with (n = 50) and without (n = 316) preeclampsia (PE) at delivery, recruited in the REPROgrammed fetal and/or maternal METAbolism (REPROMETA) study (2006-2011, Estonia). Genetic association analysis combined PE cases (n = 597) and controls (n = 623) from the REPROMETA and Finnish Genetics of Preeclampsia Consortium (2008-2011) studies. Main Outcome Measure(s): Maternal postpartum plasma STC1 was measured by ELISA (n = 366) and placental STC1 gene expression by TaqMan quantitative RT-PCR (n = 120). Genotyping was performed using Sequenom MassArray. Results: Significantly higher STC1 plasma level was measured for the PE (median, 1952 pg/mL; 1030-4284 pg/mL) compared with non-PE group (median, 1562 pg/mL; 423-3781 pg/mL; P = 3.7 = 10 = 4, Mann-Whitney U test). Statistical significance was enhanced after adjustment for cofactors (linear regression, P = 1.8 x 10(-6)). STC1 measurements were negatively correlated with maternal smoking. Prepregnancy body mass index had a positive correlation with STC1 only among PE patients (r = 0.45; P =.001). The strongest genetic association with hormone concentrations was detected for STC1 single nucleotide polymorphisms rs3758089 (C allele: minor allele frequency, 5%; linear regression: beta = 249.2 pg/mL; P =.014) and rs12678447 (G allele: minor allele frequency, 7%; beta = 147.0 pg/mL; P =.082). rs12678447 placental genotypes were significantly associated with STC1 gene expression (P =.014). The REPROMETA/Finnish Genetics of Preeclampsia Consortium metaanalysis suggested an increased risk to develop late-onset PE for the rs12678447 G allele carriers (P =.05; odds ratio = 1.38 [0.98 -1.93]). Conclusions: Increased STC1 hormone represents a hallmark of late-onset PE. STC1 gene variants modulate placental gene expression and maternal hormone levels.
Subject: EXPRESSION
LACTATION
GESTATION
PROFILE
KIDNEY
GROWTH
MODEL
MICE
3123 Gynaecology and paediatrics
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
jcem4799.pdf 602.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record